Skip to content
Screener

King Pharmaceuticals KG Deferred Tax Assets

Deferred Tax Assets at other companies

Everest Group logo
Everest GroupEG
$933M-17.1%
SiriusPoint logo
SiriusPointSPNT
$267.4M-10.0%
Skyward Specialty Insurance Group, Inc. logo
Skyward Specialty Insurance Group, Inc.SKWD
$47.99M+67.0%
Selective Insurance Group logo
Selective Insurance GroupSIGI
$137.88M+14.3%
W.R. Berkley logo
W.R. BerkleyWRB
-$77.27M+42.7%
Universal Insurance Holdings logo
Universal Insurance HoldingsUVE
$14.24M-5.7%

Other financials

Income statement

See full
Revenue$6.7M+20.1%
Net income-$8.1M-112%
EPS (diluted)-$1.03-107%

Balance sheet

See full
Cash & equivalents$26.3M-43.2%
Total debt$177.0M+0.6%
Total equity$114.0M-24.1%
Total assets$919.6M-20.7%

Cash flow

See full
Operating cash flow-$25.8M-30.0%

Valuation

See full
Market cap$69.71M-73.8%
Enterprise value$220.43M-44.4%
P/E1.4×
P/S1.6×-30.3×

Profitability

See full
Net margin110.8%

Returns & leverage

See full
Return on equity37.4%
Debt / equity1.6×+0.4×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsDeferredIncome.

The source filing: King Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →

Filed
Aug 7, 2026, 8:49 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054606

FAQ

What is King Pharmaceuticals's deferred tax assets?
King Pharmaceuticals (KG) reported deferred tax assets of $0 in Q2 2026.
What does deferred tax assets mean?
Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.

Ask your AI about King Pharmaceuticals's deferred tax assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude